A different approach found that NSCLC patients produced auto-antibodies to CCT5 at higher levels than healthy individuals; so, screening for these auto-autoantibodies in sera could be a novel diagnostic for cancer (Gao et al., 2017). The gene discussed is CCT5; the disease is cancer.